Jennifer Hill, MD
Urogynecology and Reconstructive Pelvic Surgery · Riverhead, NYNPI 1932390150
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Axonics, Inc. at 46.6% of the total. 2025 is the largest year on record at $5,286, 8.7 times the $605 reported in 2019.
Across 118 payments — averaging $107.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$6K
- Boston Scientific$5K
- Astellas Pharma US Inc$677
- Intuitive Surgical$220
- Caldera Medical, Inc$107
- Boehringer Ingelheim$97
- plus $266 from 11 others
What the payments were for
- Speaking & faculty fees$5,25841%
- Travel & lodging$3,01124%
- Food & beverage$4,05132%
- Education$2992%
- Gifts$1071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 68 | $5,926 |
| Boston Scientific | 11 | $5,432 |
| Astellas Pharma US Inc | 21 | $677 |
| Intuitive Surgical | 1 | $220 |
| Caldera Medical, Inc | 1 | $107 |
| Boehringer Ingelheim | 1 | $97 |
| AbbVie(2 entities) | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Davol Inc. | 1 | $35 |
| Therapeuticsmd, Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Geistlich Pharma, North America, Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
| Coloplast | 1 | $12 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$8,060
- Bulkamid$2,546
- Axonics r-SNM System$683
- Da Vinci Surgical System$220
- Solyx SIS System$164
- MYRBETRIQ$125
- Desara$107
How this compares
$12,725 in reported general payments places this provider in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 112 | $107,007 |
| MyrbetriqMirabegron | 55 | $63,725 |
| Estradiol | 143 | $11,574 |
| EstringEstradiol | 15 | $7,925 |
| Mirabegron ErMirabegron | 11 | $6,798 |
| Solifenacin Succinate | 34 | $3,888 |
| Desmopressin Acetate | 23 | $3,346 |
| CefuroximeCefuroxime Axetil | 89 | $2,012 |
| Estradiol (Twice Weekly)Estradiol | 12 | $1,711 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 50 | $1,414 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 51 | $1,053 |
| Tamsulosin Hcl | 46 | $1,013 |
| ProgesteroneProgesterone, Micronized | 17 | $772 |
| Clobetasol Propionate | 21 | $620 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $45 | $107,007112 claims |
| Astellas Pharma US IncMyrbetriq | $677 | $63,72555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in Riverhead
- Jason KimStony Brook$346K
- Dara ShalomGreat Neck$94K
- Harvey WinklerGreat Neck$81K
- Robert MoldwinNew Hyde Park$35K
- Nitya AbrahamBronx$24K
- Cornelius VerhoestPoughkeepsie$21K
- Abeer EddibCheektowaga$19K
- Wai LeeNew Hyde Park$17K
- Doreen ChungNew Hyde Park$14K
- Ido SirotaNew York$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.